Shanghai Accelerates 'Future Life' Strategy to Lead Global Biopharma Innovation
Shanghai is aggressively implementing a new 'first-class business environment' framework designed to anchor its position as the global epicenter for 'Future Life' industries. The initiative prioritizes regulatory breakthroughs in gene therapy and synthetic biology while expanding the Zhangjiang-Lingang biopharma corridor.